IN8bio Reports Second Quarter 2025 Financial Results and Recent Business Highlights
IN8bio (Nasdaq: INAB) reported significant clinical progress and financial results for Q2 2025. The company achieved a remarkable milestone in its INB-200 glioblastoma trial, with one patient surpassing four years without progression. Clinical data presented at ASCO 2025 showed patients receiving multiple doses achieved median progression-free survival of 16.1 months, more than double the standard-of-care outcome.
The company received recognition for its DeltEx鈩� manufacturing platform and presented promising preclinical data for INB-619, a gamma-delta T cell engager showing potential in lupus treatment. Financial results showed R&D expenses of $2.5M and G&A expenses of $2.7M, with a cash position of $13.2M extending runway into June 2026.
IN8bio (Nasdaq: INAB) ha riportato importanti progressi clinici e risultati finanziari per il secondo trimestre del 2025. L'azienda ha raggiunto un traguardo significativo nel suo trial INB-200 sul glioblastoma, con un paziente che ha superato i quattro anni senza progressione della malattia. I dati clinici presentati all'ASCO 2025 hanno mostrato che i pazienti trattati con dosi multiple hanno ottenuto una sopravvivenza libera da progressione mediana di 16,1 mesi, pi霉 del doppio rispetto ai risultati standard di cura.
L'azienda ha ricevuto riconoscimenti per la sua piattaforma di produzione DeltEx鈩� e ha presentato dati preclinici promettenti per INB-619, un attivatore delle cellule T gamma-delta con potenziale nel trattamento del lupus. I risultati finanziari hanno evidenziato spese in R&S di 2,5 milioni di dollari e spese amministrative di 2,7 milioni di dollari, con una liquidit脿 di 13,2 milioni di dollari che garantisce la copertura finanziaria fino a giugno 2026.
IN8bio (Nasdaq: INAB) inform贸 avances cl铆nicos significativos y resultados financieros para el segundo trimestre de 2025. La compa帽铆a alcanz贸 un hito notable en su ensayo INB-200 para glioblastoma, con un paciente que super贸 los cuatro a帽os sin progresi贸n. Los datos cl铆nicos presentados en ASCO 2025 mostraron que los pacientes que recibieron m煤ltiples dosis lograron una supervivencia libre de progresi贸n mediana de 16.1 meses, m谩s del doble del resultado est谩ndar de atenci贸n.
La empresa recibi贸 reconocimiento por su plataforma de fabricaci贸n DeltEx鈩� y present贸 datos precl铆nicos prometedores para INB-619, un activador de c茅lulas T gamma-delta que muestra potencial en el tratamiento del lupus. Los resultados financieros indicaron gastos en I+D de 2.5 millones de d贸lares y gastos administrativos de 2.7 millones de d贸lares, con una posici贸n de efectivo de 13.2 millones de d贸lares que extiende la liquidez hasta junio de 2026.
IN8bio (雮橃姢雼�: INAB)電� 2025雲� 2攵勱赴 鞛勳儊 歆勳爠瓿� 鞛 瓴瓣臣毳� 氚滍憸頄堨姷雼堧嫟. 须岇偓电� INB-200 甑愲靹疙彫膦� 鞛勳儊鞁滍棙鞐愳劀 欷戩殧頃� 鞚挫爼響滊ゼ 雼劚頄堨溂氅�, 頃� 頇橃瀽電� 4雲� 鞚挫儊 氍挫頄� 靸來儨毳� 鞙犾頄堨姷雼堧嫟. ASCO 2025鞐愳劀 氚滍憸霅� 鞛勳儊 雿办澊韯办棎 霐半ゴ氅�, 雼ろ殞 韴棳 頇橃瀽霌れ潃 氍挫頄� 靸濎〈 欷戩暀臧� 16.1臧滌洈鞚� 旮半頄堨溂氅�, 鞚措姅 響滌 旃橂 瓴瓣臣鞚� 霊� 氚� 鞚挫儊鞛呺媹雼�.
须岇偓电� DeltEx鈩� 鞝滌“ 頂岆灚韽�鞙茧 鞚胳爼氚涭晿鞙茧┌, 耄懜鞀� 旃橂 臧�電レ劚鞚� 氤挫澊電� 臧愲-雿疙儉 T靹疙彫 頇滌劚鞝� INB-619鞚� 鞙犽頃� 鞝勳瀯靸� 雿办澊韯半ゼ 氚滍憸頄堨姷雼堧嫟. 鞛 瓴瓣臣電� 鞐瓣惮臧滊皽牍� 250毵� 雼煬鞕赌 鞚茧皹甏�毽箘 270毵� 雼煬毳� 旮半頄堨溂氅�, 順勱笀 氤挫湢鞎§潃 1320毵� 雼煬搿� 2026雲� 6鞗旉箤歆� 鞖挫榿 鞛愱笀鞚� 頇曤炒頄堨姷雼堧嫟.
IN8bio (Nasdaq : INAB) a annonc茅 des progr猫s cliniques significatifs et des r茅sultats financiers pour le deuxi猫me trimestre 2025. La soci茅t茅 a atteint une 茅tape remarquable dans son essai INB-200 sur le glioblastome, avec un patient d茅passant quatre ans sans progression. Les donn茅es cliniques pr茅sent茅es 脿 l'ASCO 2025 ont montr茅 que les patients recevant plusieurs doses ont obtenu une survie sans progression m茅diane de 16,1 mois, soit plus du double du r茅sultat standard de soins.
L'entreprise a 茅t茅 reconnue pour sa plateforme de fabrication DeltEx鈩� et a pr茅sent茅 des donn茅es pr茅cliniques prometteuses pour INB-619, un activateur des cellules T gamma-delta montrant un potentiel dans le traitement du lupus. Les r茅sultats financiers ont r茅v茅l茅 des d茅penses en R&D de 2,5 millions de dollars et des d茅penses administratives de 2,7 millions de dollars, avec une tr茅sorerie de 13,2 millions de dollars assurant une visibilit茅 financi猫re jusqu'en juin 2026.
IN8bio (Nasdaq: INAB) meldete bedeutende klinische Fortschritte und Finanzergebnisse f眉r das zweite Quartal 2025. Das Unternehmen erreichte einen bemerkenswerten Meilenstein in seiner INB-200 Glioblastom-Studie, bei der ein Patient mehr als vier Jahre ohne Krankheitsprogression 眉berstand. Klinische Daten, die auf der ASCO 2025 pr盲sentiert wurden, zeigten, dass Patienten mit mehreren Dosen eine medianes progressionsfreies 脺berleben von 16,1 Monaten erreichten, was mehr als dem Doppelten des Standardbehandlungs-Ergebnisses entspricht.
Das Unternehmen erhielt Anerkennung f眉r seine DeltEx鈩� Fertigungsplattform und pr盲sentierte vielversprechende pr盲klinische Daten zu INB-619, einem Gamma-Delta-T-Zell-Engager mit Potenzial zur Behandlung von Lupus. Die Finanzergebnisse zeigten F&E-Ausgaben von 2,5 Mio. USD und Verwaltungskosten von 2,7 Mio. USD sowie eine Liquidit盲tsposition von 13,2 Mio. USD, die die finanzielle Laufzeit bis Juni 2026 verl盲ngert.
- None.
- Strategic pause implemented on INB-400 clinical trial activities
- Reduced personnel-related costs following pipeline prioritization
Insights
IN8bio shows promising GBM survival data with 16.1-month mPFS, but financial runway concerns remain despite cost-cutting efforts.
IN8bio's second quarter results showcase impressive clinical data for their gamma-delta T cell therapy in glioblastoma (GBM). The 16.1-month median progression-free survival in patients receiving multiple doses of INB-200 represents more than double the typical 6.9 months seen with standard-of-care. The four-year progression-free patient is particularly noteworthy in GBM, where long-term survival is exceedingly rare.
However, the financial picture reveals both progress and challenges. The company has managed to reduce quarterly R&D expenses by 52% to
Despite these cost-cutting measures, their cash position of
The expansion into autoimmune applications with their INB-619 T cell engager program represents a potential strategic pivot to broaden their therapeutic scope beyond oncology. This diversification could create additional value inflection points but also divides resources across more programs.
The recognition of their DeltEx鈩� manufacturing platform suggests operational advantages in cell therapy production鈥攃ritical for commercialization鈥攂ut the prioritization announcement from 2024 indicates the company has had to make difficult pipeline decisions to extend runway, which may limit near-term catalysts.
IN8bio's gamma-delta T cell therapy shows remarkable durability in GBM with manufacturing platform validation enhancing commercial potential.
The clinical data from IN8bio's INB-200 program represents a potentially significant advancement in glioblastoma treatment. GBM is notoriously treatment-resistant, with standard-of-care typically yielding progression-free survival of around 7 months. The 16.1-month mPFS in multiple-dose patients indicates their gamma-delta T cell approach may be overcoming key resistance mechanisms. Most striking is the patient surpassing four years without progression鈥攁n extraordinary outlier in a disease where long-term survivors are exceedingly rare.
From a technical perspective, the recognition of their DeltEx鈩� manufacturing platform at ISCT 2025 is particularly noteworthy. Cell therapy manufacturing remains one of the most significant barriers to commercial success in the field. Challenges in consistency, scalability, and cost-efficiency have hindered many otherwise promising therapies. The award suggests IN8bio may have solved critical manufacturing hurdles that plague the cell therapy industry.
Their expansion into autoimmune applications with the gamma-delta T cell engager (INB-619) demonstrates the platform's versatility. The preclinical data showing targeted B cell depletion in lupus samples without significant inflammatory cytokine release addresses a key limitation of current B cell-depleting therapies. This mechanism could potentially offer improved safety profiles compared to existing treatments like rituximab, which can trigger cytokine release syndrome.
The strategic pause on the INB-400 program highlights the resource constraints facing the company. While pipeline prioritization is prudent given their financial position, it also indicates they're facing difficult development decisions. The company appears to be focusing resources on their most promising programs while maintaining a lean operational structure, which is appropriate given their runway constraints.
- Delivered an oral presentation at ASCO 2025 Annual Meeting, demonstrating extended median progression-free survival (mPFS) in patients receiving multiple doses of INB-200, including a patient remaining progression-free for over four years.
- Received the Host Region USA East Abstract Award at ISCT 2025 for IN8bio鈥檚 DeltEx鈩� manufacturing platform.
- Presented preclinical data at ASGCT 2025 on INB-619, a novel gamma-delta T cell engager, and its ability to induce pan-gamma-delta T cell expansion and target CD19+ B cells in lupus patient samples.
NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) -- . (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune diseases, today reported financial results and business highlights for the second quarter ended June 30, 2025.
Key Highlights:
Durable Four-Year PFS Milestone in Glioblastoma:
- A patient in IN8bio's INB-200 clinical trial has now surpassed four years without progression, a significant clinical milestone in front-line, grade IV glioblastoma (GBM), demonstrating the potential for extended overall survival and the durability of IN8bio鈥檚 therapy.
Positive Clinical Data Presented at ASCO 2025:
- IN8bio presented positive new data showing that GBM patients receiving multiple doses of INB-200 achieved mPFS of 16.1 months as of May 31, 2025, more than double the 6.9 months typically observed with the standard-of-care Stupp protocol.
40% of patients receiving multiple doses remain progression-free for over 18 months with no significant toxicities observed as of May 31, 2025.
Award for Innovative Cell Therapy Manufacturing:
- The Company was recognized with the Host Region USA East Abstract Award at the ISCT 2025 Annual Meeting for its DeltEx鈩� platform. IN8bio showcased its robust manufacturing processes and scalable technology platform, essential for advancing cell therapy treatments with consistency and operational efficiency.
New Preclinical Data in Autoimmune Diseases:
- IN8bio presented exciting new preclinical results at ASGCT 2025 for its innovative gamma-delta T cell engager (INB-619). INB-619 demonstrated complete, targeted depletion of harmful B cells in lupus samples without significant inflammatory cytokines, representing a potentially safer immunotherapy alternative with the ability to drive deeper B cell depletion.
William Ho, CEO and co-founder, IN8bio, commented, 鈥淲e believe this quarter clearly demonstrates our ability to deliver transformative outcomes in cancer and autoimmune disease. We had an oral presentation at ASCO, reached a remarkable four-year PFS milestone in a grade IV glioblastoma patient, demonstrated the potential of our T cell engager platform to treat autoimmune diseases, and highlighted our robust cell therapy manufacturing capabilities. We鈥檙e proud of these continued accomplishments, which demonstrate our ability to be a leader in gamma-delta T cell therapies and highlight our potential to help transform the treatment of cancer and autoimmune disease. We鈥檝e also extended our runway into June 2026.鈥�
Upcoming Anticipated Pipeline Milestones and Events
- Update on enrollment in INB-100 expansion cohort in leukemia patients
- Glioblastoma clinical update from INB-200 and INB-400 clinical trials
- Additional preclinical data from INB-619 T cell engager program for cancer and autoimmune diseases in 4Q25
Second Quarter 2025 Financial Highlights
- Research and Development (R&D) expenses:听R&D expenses were
$2.5 million for the three months ended June 30, 2025, compared with$5.2 million in the prior year. These amounts include non-cash items such as stock-based compensation (SBC) and depreciation of$0.5 million . The change was primarily due to a strategic pause on clinical trial-related activities for the INB-400 program and reduced personnel-related costs, which followed the Company鈥檚 pipeline prioritization announcement in September 2024. - General and administrative (G&A) expenses:听G&A expenses were
$2.7 million for the three months ended June 30, 2025, compared with$3.5 million for the comparable prior year period. These amounts include non-cash items such as SBC and depreciation of$0.7 million . The change was primarily due to cost savings related to personnel-related costs, director and officer insurance premiums and professional services. - Net loss:听The company reported a net loss of
$5.1 million , or$1.24 per basic and diluted common share, for the three months ended June 30, 2025, compared with a net loss of$8.6 million , or$5.51 per basic and diluted common share, for the comparable prior year period. This amount includes non-cash items such as SBC and depreciation of$1.2 million , along with one-time charges related to the Company鈥檚 pipeline prioritization announcement in September 2024. - Cash position:听As of June 30, 2025, the Company had cash of
$13.2 million , compared with$10.2 million for the comparable prior year.
About IN8bio
IN8bio is a clinical-stage biopharmaceutical company developing 纬未 T cell product candidates for unmet medical needs. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The company's lead program, INB-100, is focused on acute myeloid leukemia evaluating haplo-matched allogeneic 纬未 T cells given to patients following a hematopoietic stem cell transplant. The company is also evaluating autologous DeltEx DRI 纬未 T cells, in combination with standard of care, for glioblastoma in its INB-200 and 400 programs, and INB-600, advancing novel 纬未 T cell engagers for potential oncology and autoimmune indications. For more information about IN8bio, visit听.
Forward Looking Statements
This press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as 鈥渁ims,鈥� 鈥渁nticipates,鈥� 鈥渂elieves,鈥� 鈥渃ould,鈥� 鈥渆stimates,鈥� 鈥渆xpects,鈥� 鈥渇orecasts,鈥� 鈥済oal,鈥� 鈥渋ntends,鈥� 鈥渕ay,鈥� 鈥減lans,鈥� 鈥減ossible,鈥� 鈥減otential,鈥� 鈥渟eeks,鈥� 鈥渨ill鈥� and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding: INB-200鈥檚 (i) treatment potential for patients with GBM, (ii) extended survival potential and durability compared to outcomes observed in other clinical trials of IDH-mutant glioma patients; INB-619鈥檚 ability to (i) efficiently target CD19+ B cells in lupus patient samples and induce pan-纬未 T cell expansion without significant inflammatory cytokines and (ii) provide a safer immunotherapy alternative with the ability to drive deeper B cell depletion; IN8bio鈥檚 DeltEx platform鈥檚 ability to help advance cell therapy treatments with consistency and operational efficiency; IN8bio鈥檚 ability to (i) deliver transformative outcomes in cancer and autoimmune diseases and (ii) be a leader in gamma-delta T cell therapies; IN8bio鈥檚 ability to achieve other anticipated milestones, including expected presentations and data readouts from its trials and advancement of clinical development plans; and other statements that are not historical fact. IN8bio may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: risks to site initiation, clinical trial commencement, patient enrollment and follow-up, as well as IN8bio鈥檚 ability to meet anticipated deadlines and milestones; uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development of IN8bio鈥檚 product candidates; the risk that IN8bio may be unable to raise additional capital and could be forced to delay, further reduce or to explore other strategic options for certain of our development programs, or even terminate its operations; IN8bio鈥檚 ability to continue to operate as a going concern; the risk that IN8bio may not realize the intended benefits of its DeltEx platform; availability and timing of results from preclinical studies and clinical trials; whether the outcomes of preclinical studies will be predictive of clinical trial results; whether initial or interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; the risk that trials and studies may be delayed and may not have satisfactory outcomes; potential adverse effects arising from the testing or use of IN8bio鈥檚 product candidates; the uncertainty of regulatory approvals to conduct trials or to market products; IN8bio鈥檚 reliance on third parties, including licensors and clinical research organizations; and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, are described in greater detail in the section entitled 鈥淩isk Factors鈥� in our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on May 7, 2025, as well as in other filings IN8bio may make with the SEC in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and IN8bio expressly disclaims any obligation to update any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.
| IN8BIO, INC. CONDENSED BALANCE SHEETS (In thousands, except share and per share data) | ||||||||
| 听 | ||||||||
| 听 | 听 | June 30, | 听 | 听 | ||||
| 听 | 听 | 听2025听 | 听 | December听31, | ||||
| 听 | 听 | (unaudited) | 听 | 听2024听 | ||||
| Assets | 听 | 听 | 听 | (Note 2) | ||||
| Current assets | 听 | 听 | 听 | 听 | ||||
| Cash | 听 | $ | 13,226 | 听 | 听 | $ | 11,120 | 听 |
| Prepaid expenses and other current assets | 听 | 听 | 515 | 听 | 听 | 听 | 1,458 | 听 |
| Total Current Assets | 听 | 听 | 13,741 | 听 | 听 | 听 | 12,578 | 听 |
| Non-current assets | 听 | 听 | 听 | 听 | ||||
| Property and equipment, net | 听 | 听 | 2,347 | 听 | 听 | 听 | 2,858 | 听 |
| Restricted cash | 听 | 听 | 271 | 听 | 听 | 听 | 266 | 听 |
| Right-of-use assets - finance leases | 听 | 听 | 542 | 听 | 听 | 听 | 1,068 | 听 |
| Right-of-use assets - operating leases | 听 | 听 | 2,195 | 听 | 听 | 听 | 3,899 | 听 |
| Other non-current assets | 听 | 听 | 275 | 听 | 听 | 听 | 275 | 听 |
| Total Non-Current Assets | 听 | 听 | 5,630 | 听 | 听 | 听 | 8,366 | 听 |
| Total Assets | 听 | $ | 19,371 | 听 | 听 | $ | 20,944 | 听 |
| Liabilities and Stockholders' Equity | 听 | 听 | 听 | 听 | ||||
| Liabilities | 听 | 听 | 听 | 听 | ||||
| Current liabilities | 听 | 听 | 听 | 听 | ||||
| Accounts payable | 听 | $ | 379 | 听 | 听 | $ | 389 | 听 |
| Accrued expenses and other current liabilities | 听 | 听 | 635 | 听 | 听 | 听 | 1,047 | 听 |
| Short-term finance lease liability | 听 | 听 | 404 | 听 | 听 | 听 | 694 | 听 |
| Short-term operating lease liability | 听 | 听 | 536 | 听 | 听 | 听 | 953 | 听 |
| Total Current Liabilities | 听 | 听 | 1,954 | 听 | 听 | 听 | 3,083 | 听 |
| Long-term finance lease liability | 听 | 听 | 126 | 听 | 听 | 听 | 295 | 听 |
| Long-term operating lease liability | 听 | 听 | 2,052 | 听 | 听 | 听 | 3,088 | 听 |
| Total Non-Current Liabilities | 听 | 听 | 2,178 | 听 | 听 | 听 | 3,383 | 听 |
| Total Liabilities | 听 | 听 | 4,132 | 听 | 听 | 听 | 6,466 | 听 |
| Stockholders' Equity | 听 | 听 | 听 | 听 | ||||
| Preferred stock, par value 10,000,000 shares authorized at June 30, 2025 and December 31, 2024, respectively; no shares issued and outstanding | 听 | 听 | 鈥� | 听 | 听 | 听 | 鈥� | 听 |
| Common stock, par value 490,000,000 shares authorized at June 30, 2025 and December 31, 2024; 4,078,139 and 2,416,066 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively(1) | 听 | 听 | 10 | 听 | 听 | 听 | 7 | 听 |
| Additional paid-in capital | 听 | 听 | 147,529 | 听 | 听 | 听 | 136,127 | 听 |
| Accumulated deficit | 听 | 听 | (132,300 | ) | 听 | 听 | (121,656 | ) |
| Total Stockholders' Equity | 听 | 听 | 15,239 | 听 | 听 | 听 | 14,478 | 听 |
| Total Liabilities and Stockholders' Equity | 听 | $ | 19,371 | 听 | 听 | $ | 20,944 | 听 |
| IN8BIO, INC. CONDENSED STATEMENTS OF OPERATIONS (In thousands, except share and per share data) (Unaudited) | ||||||||||||||||
| 听 | ||||||||||||||||
| 听 | 听 | Three Months Ended June听30, | 听 | Six Months Ended June听30, | ||||||||||||
| 听 | 听 | 听 | 2025 | 听 | 听 | 听 | 2024 | 听 | 听 | 听 | 2025 | 听 | 听 | 听 | 2024 | 听 |
| Operating expenses: | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||||||
| Research and development | 听 | $ | 2,487 | 听 | 听 | $ | 5,156 | 听 | 听 | $ | 5,459 | 听 | 听 | $ | 10,059 | 听 |
| General and administrative | 听 | 听 | 2,714 | 听 | 听 | 听 | 3,533 | 听 | 听 | 听 | 5,402 | 听 | 听 | 听 | 7,275 | 听 |
| Total operating expenses | 听 | 听 | 5,201 | 听 | 听 | 听 | 8,689 | 听 | 听 | 听 | 10,861 | 听 | 听 | 听 | 17,334 | 听 |
| Interest income | 听 | 听 | 107 | 听 | 听 | 听 | 60 | 听 | 听 | 听 | 217 | 听 | 听 | 听 | 143 | 听 |
| Loss from operations | 听 | 听 | (5,094 | ) | 听 | 听 | (8,629 | ) | 听 | 听 | (10,644 | ) | 听 | 听 | (17,191 | ) |
| Net loss | 听 | $ | (5,094 | ) | 听 | $ | (8,629 | ) | 听 | $ | (10,644 | ) | 听 | $ | (17,191 | ) |
| Net loss per share 鈥撯�塨asic and diluted | 听 | $ | (1.24 | ) | 听 | $ | (5.51 | ) | 听 | $ | (3.65 | ) | 听 | $ | (11.59 | ) |
| Weighted-average number of shares used in computing net loss per common share, basic and diluted(1) | 听 | 听 | 4,119,153 | 听 | 听 | 听 | 1,566,951 | 听 | 听 | 听 | 2,920,157 | 听 | 听 | 听 | 1,483,240 | 听 |
Contacts:
IN8bio, Inc.
Patrick McCall
646.933.5603
Media Contact:
KKH Advisors
Kimberly Ha
917.291.5744
FAQ
What were the key clinical results for IN8bio's (INAB) glioblastoma treatment in Q2 2025?
How much cash does IN8bio (INAB) have as of Q2 2025 and what is their runway?
What progress did IN8bio (INAB) make in autoimmune disease treatment?
How did IN8bio's (INAB) Q2 2025 financial results compare to the previous year?
What upcoming milestones does IN8bio (INAB) anticipate?
